Turanaxyl 10mg

Turanaxyl — Kalpa Pharmaceuticals Turinabol 10mg

Turanaxyl delivers 10 mg of 4-chlorodehydromethyltestosterone per tablet. Manufactured by Kalpa Pharmaceuticals, this oral anabolic is engineered for athletes pursuing quality hypertrophy without estrogenic complications.

The compound promotes steady strength accretion and visible muscular refinement. It is particularly valued for recomposition phases where dry tissue preservation takes priority over bulk accumulation.

Overview

4-chlorodehydromethyltestosterone is a modified testosterone derivative bearing a chloro substitution at the C4 position. This structural alteration eliminates aromatization potential while preserving anabolic efficacy.

Originally synthesized for athletic performance enhancement, the molecule improves nitrogen retention and contractile protein synthesis. Users experience progressive power increases without the subcutaneous bloating associated with estrogenic compounds.

The C17-alpha alkylation ensures high oral bioavailability. This modification protects the hormone during hepatic first-pass metabolism but imposes measurable strain on liver enzymes.

Kalpa Pharmaceuticals manufactures each batch under strict quality protocols. Tablet uniformity and active concentration consistency support precise daily dosing.

Benefits

• Dry Hypertrophy: Promotes lean, dense muscle accretion without fluid retention or estrogenic puffiness.
• Zero Aromatization Risk: The C4 chloro substitution prevents conversion to estradiol, eliminating gynecomastia and water retention concerns.
• Enhanced Definition: Supports vascularity and muscular separation by avoiding subcutaneous edema.
• Steady Power Gains: Improves force output and training density through increased nitrogen retention and red blood cell support.
• Recomposition Utility: Ideal for body recomposition cycles where simultaneous fat reduction and lean tissue preservation are targeted.

Main Features

• 10 mg oral tablets of 4-chlorodehydromethyltestosterone
• Non-aromatizing C4 chloro-substituted testosterone derivative
• C17-alpha alkylated for high oral bioavailability
• Mild androgenic profile with moderate anabolic activity
• Suitable for standalone or stacked protocols
• Pharmaceutical-grade tablet manufacturing

Ingredients

Each tablet contains 10 mg of 4-chlorodehydromethyltestosterone as the active pharmaceutical ingredient.

Inactive excipients include microcrystalline cellulose, magnesium stearate, and pharmaceutical-grade binders to ensure tablet hardness and dissolution consistency.

All raw materials are validated for chemical identity and purity prior to compression.

How to Use

Ingest tablets with water, preferably alongside a light meal to reduce gastrointestinal irritation.

Split the daily total into two administrations—morning and evening—to maintain stable plasma concentrations throughout the day.

Store the container in a cool, dry environment away from direct sunlight. Keep the desiccant pouch intact to prevent moisture degradation.

Dosage

Male users typically administer 30–50 mg daily across a 6–8 week protocol. Divide the total into two or three doses to moderate hepatic exposure.

Beginners may initiate at the lower end of the range to assess individual tolerance and androgenic response.

Female athletes should exercise extreme caution. Doses of 5–10 mg daily represent the maximum threshold before virilization risk becomes significant.

Limit continuous administration to 8 weeks maximum due to C17-alpha alkylation hepatotoxicity.

Side Effects

Hepatic enzyme elevations are expected with all C17-alkylated oral steroids. Regular liver function monitoring and hepatoprotective supplementation are essential.

The compound suppresses endogenous testosterone production through hypothalamic-pituitary-gonadal axis inhibition. A structured Post-Cycle Therapy protocol is mandatory following cessation.

Lipoprotein ratios may shift unfavorably. HDL cholesterol frequently decreases while LDL increases, necessitating cardiovascular monitoring.

Androgenic manifestations such as mild acne or increased sebum production can occur. These are generally dose-dependent and manageable.

Safety Information

This product is intended exclusively for research purposes and use by qualified adults under appropriate supervision. It is not suitable for minors or individuals with pre-existing hepatic conditions.

Hepatoprotective agents such as TUDCA or N-acetylcysteine should accompany every cycle. Avoid alcohol and all other hepatotoxic substances during the active phase.

A comprehensive PCT using Clomiphene or Tamoxifen must begin within days of the final tablet. This restores natural testosterone synthesis and preserves accrued tissue.

Monitor blood pressure and fasting lipids throughout the protocol. Maintain a heart-healthy diet and regular cardiovascular exercise.

Discontinue immediately and seek medical evaluation if jaundice, severe abdominal pain, or persistent fatigue develop.